Biologics are poised to redefine the treatment protocols in the Urological Medications Market. Unlike traditional small-molecule drugs, biologics offer highly specific targeting capabilities, which are essential for treating complex inflammatory conditions and late-stage cancers of the urinary tract. This precision leads to higher response rates and a reduced need for invasive interventions....